

**JOHNSON & JOHNSON**  
**REPORTED SALES vs. PRIOR PERIOD**  
**\$MM**

	<u>1Q 2007</u>	<u>1Q 2006</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>	<u>2007 YTD</u>	<u>2006 YTD</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>
<b><u>PHARMACEUTICAL SEGMENT*</u></b>										
<b><u>ACIPHEX/PARIET</u></b>										
US	159	146	9%	9%	--	159	146	9%	9%	--
Intl	177	160	10%	4%	6%	177	160	10%	4%	6%
WW	336	306	10%	7%	3%	336	306	10%	7%	3%
<b><u>Anti-Psychotics <sup>(1)</sup></u></b>										
US	710	585	21%	21%	--	710	585	21%	21%	--
Intl	468	433	8%	2%	6%	468	433	8%	2%	6%
WW	1,178	1,018	16%	13%	3%	1,178	1,018	16%	13%	3%
<b><u>CONCERTA</u></b>										
US	200	193	3%	3%	--	200	193	3%	3%	--
Intl	52	42	25%	18%	7%	52	42	25%	18%	7%
WW	252	235	7%	6%	1%	252	235	7%	6%	1%
<b><u>DURAGESIC</u></b>										
US	116	110	5%	5%	--	116	110	5%	5%	--
Intl	187	215	-13%	-18%	5%	187	215	-13%	-18%	5%
WW	303	325	-7%	-10%	3%	303	325	-7%	-10%	3%
<b><u>EPREX/PROCRIT</u></b>										
US	530	527	1%	1%	--	530	527	1%	1%	--
Intl	287	259	11%	4%	7%	287	259	11%	4%	7%
WW	817	786	4%	2%	2%	817	786	4%	2%	2%
<b><u>Hormonal Contraceptives</u></b>										
US	174	198	-12%	-12%	--	174	198	-12%	-12%	--
Intl	63	56	13%	8%	5%	63	56	13%	8%	5%
WW	237	254	-7%	-8%	1%	237	254	-7%	-8%	1%
<b><u>LEVAQUIN</u></b>										
US	460	393	17%	17%	--	460	393	17%	17%	--
Intl	15	10	50%	54%	-4%	15	10	50%	54%	-4%
WW	475	403	18%	18%	0%	475	403	18%	18%	0%
<b><u>REMICADE</u></b>										
US	600	566	6%	6%	--	600	566	6%	6%	--
Intl	131	115	14%	14%	0%	131	115	14%	14%	0%
WW	731	681	7%	7%	0%	731	680	7%	7%	0%
<b><u>TOPAMAX</u></b>										
US	501	373	34%	34%	--	501	373	34%	34%	--
Intl	109	98	11%	5%	6%	109	98	11%	5%	6%
WW	610	471	30%	29%	1%	610	471	30%	29%	1%

<sup>(1)</sup> Includes Risperdal, Risperdal Consta & Invega

\*Selected Areas  
(unaudited)

\*\*Operational growth excludes the effect of currency

**JOHNSON & JOHNSON**  
**REPORTED SALES vs. PRIOR PERIOD**  
**\$MM**

	<u>1Q 2007</u>	<u>1Q 2006</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>	<u>2007 YTD</u>	<u>2006 YTD</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>
<b><u>MEDICAL DEVICES AND DIAGNOSTICS*</u></b>										
<u>Cordis</u>										
US	424	530	-20%	-20%	--	424	530	-20%	-20%	--
Intl	504	545	-7%	-10%	3%	504	545	-7%	-10%	3%
WW	928	1,075	-14%	-15%	1%	928	1,075	-14%	-15%	1%
<u>DePuy</u>										
US	678	644	5%	5%	--	678	644	5%	5%	--
Intl	479	395	21%	13%	8%	479	395	21%	13%	8%
WW	1,157	1,039	11%	8%	3%	1,157	1,039	11%	8%	3%
<u>Ethicon</u>										
US	344	296	16%	16%	--	344	296	16%	16%	--
Intl	526	478	10%	4%	6%	526	478	10%	4%	6%
WW	870	774	12%	9%	3%	870	774	12%	9%	3%
<u>Ethicon Endo-Surgery</u>										
US	417	380	10%	10%	--	417	380	10%	10%	--
Intl	474	414	15%	9%	6%	474	414	15%	9%	6%
WW	891	794	12%	9%	3%	891	794	12%	9%	3%
<u>LifeScan</u>										
US	292	288	1%	1%	--	292	288	1%	1%	--
Intl	257	216	19%	12%	7%	257	216	19%	12%	7%
WW	549	504	9%	6%	3%	549	504	9%	6%	3%
<u>Ortho-Clinical Diagnostics</u>										
US	219	199	10%	10%	--	219	199	10%	10%	--
Intl	174	171	2%	-3%	5%	174	171	2%	-3%	5%
WW	393	370	6%	4%	2%	393	370	6%	4%	2%
<u>Total Vision Care</u>										
US	195	172	14%	14%	--	195	172	14%	14%	--
Intl	318	269	18%	16%	2%	318	269	18%	16%	2%
WW	513	441	16%	15%	1%	513	441	16%	15%	1%

\*Selected Areas  
(unaudited)

\*\*Operational growth excludes the effect of currency

**JOHNSON & JOHNSON**  
**REPORTED SALES vs. PRIOR PERIOD**  
**\$MM**

	<u>1Q 2007</u>	<u>1Q 2006</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>	<u>2007 YTD</u>	<u>2006 YTD</u>	<u>Reported</u>	<u>% Change Operational**</u>	<u>Currency</u>
<b><u>CONSUMER SEGMENT* (2)</u></b>										
<u>Skin Care</u>										
US	357	318	13%	13%	--	357	318	13%	13%	--
Intl	407	341	19%	13%	6%	407	341	19%	13%	6%
WW	764	659	16%	13%	3%	764	659	16%	13%	3%
<u>Baby &amp; Kids Care</u>										
US	109	103	5%	5%	--	109	103	5%	5%	--
Intl	338	303	12%	7%	5%	338	303	12%	7%	5%
WW	447	406	10%	6%	4%	447	406	10%	6%	4%
<u>Oral Care (3)</u>										
US	203	NA	--	--	--	203	--	--	--	--
Intl	156	NA	--	--	--	156	--	--	--	--
WW	359	NA	--	--	--	359	--	--	--	--
<u>OTC/Nutritionals</u>										
US	655	445	47%	47%	--	655	445	47%	47%	--
Intl	602	208	189%	183%	6%	602	208	189%	183%	6%
WW	1,257	653	92%	90%	2%	1,257	653	92%	90%	2%
<u>Women's Health</u>										
US	163	148	10%	10%	--	163	148	10%	10%	--
Intl	258	251	3%	-2%	5%	258	251	3%	-2%	5%
WW	421	399	6%	3%	3%	421	399	6%	3%	3%

(2) 2007 Includes sales from acquisition of PCH

(3) Oral Care not disclosed in 2006

\*Selected Areas  
(unaudited)

\*\*Operational growth excludes the effect of currency